Compliance with deferoxamine infusions is related to survival in beta-thalassemia major. Kaplan-Meier analysis of survival in 257 consecutive thalassemic patients by the number of days deferoxamine infusions were administered per year. Adapted from Gabutti V and Piga A. Acta Haematol. 1996;95:26–36, with permission from S. Karger AG, Basel.